Berberine Suppresses Interleukin-1β-Induced MUC5AC Gene Expression in Human Airway Epithelial Cells

Kyung Rok Kim, MD1, Na Hyun Kim, MD1, Yuna Park, MD1, Ji Hoon Kim, MD1, Eun Jung Lee, MD1 and Kyung-Su Kim, MD1,2

1Department of Otorhinolaryngology and 2Human Barrier Research Institute, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

ABSTRACT

Objectives: The aim of this study was to investigate whether berberine suppresses interleukin (IL)-1β-induced MUC5AC gene expression in human airway epithelial cells and, if so, to determine which mitogen-activated protein kinases (MAPKs) are related to MUC5AC gene suppression. Materials and Methods: MUC5AC mRNA and protein levels were measured using reverse transcription-polymerase chain reaction (PCR), real-time PCR, and western blot analysis in cultured NCI-H292 human airway epithelial cells. Results: IL-1β-induced expressions of MUC5AC mRNA and protein were significantly suppressed in cells pretreated with 25 µM of berberine. Levels of MAPK proteins were determined by western blot analysis after pretreatment with 25 µM berberine. Berberine suppressed phosphorylation of extracellular signal-regulated kinase (ERK) and p38 MAPK, but there was no change in the expression of JNK. Suppression of IL-1β-induced MUC5AC mRNA was also observed in cells pretreated with ERK- or p38 MAPK-specific inhibitors, suggesting that berberine suppresses IL-1β-induced expression of MUC5AC mRNA, which involves the ERK- and p38 MAPK-dependent pathways. Conclusion: Berberine suppresses IL-1β-induced MUC5AC gene expression in human airway epithelial cells via the ERK- and p38 MAPK-dependent pathways; therefore, berberine may be considered as a possible anti-hypersecretory agent for inflammatory airway diseases.

KEY WORDS: Berberine · Mucin 5AC · Epithelial cells · Mitogen-activated protein kinases.

INTRODUCTION

Sinusitis, bronchitis, and bronchial asthma have a common characteristic, excessive secretion of mucus. The mechanism for mucus secretion is mediated by various cytokines, peptides, inflammatory mediators, and mucin genes such as up-regulated MUC5AC or MUC8.1,2) According to studies on MUC5AC expression, overexpression of MUC5AC induced by interleukin (IL)-1β occurs in airway epithelial cells by activation of mitogen-activated protein kinases (MAPKs) and stress-activated protein kinase-1-cAMP response element-binding pathways in a sequential cascade. This finding suggests a treatment strategy for inflammatory airway diseases through the control of mucus hypersecretion.3)

Berberine has been extensively studied for its multiple biological and pharmacological activities in various diseases, including respiratory diseases. Traditionally, it has been used as antifungal, anti-inflammatory, anti-viral agents, and also for respiratory disorders. There is some evidence to support its use in the treatment of heart failure, malaria, diabetes, glaucoma, hypercholesterolemia, diarrhea, trachoma, and leishmaniasis.4-6) Berberine has similar pharmacological effects to clonidine, an α-adrenergic agonist, and interacts with an α-adrenergic receptor.7) Moreover, berberine inhibits release of TNF-α.8) As MUC5AC expression is known to be up-regulated by TNF-α, we formulated a hypothesis that berberine suppresses MUC5AC gene expression in human airway epithelial cells. However, there is no evidence that berberine can suppress mucin secretion in human airway epithelium.

Therefore, the aim of this study was to investigate whether berberine suppresses IL-1β-induced MUC5AC gene expression in human airway epithelial cells and, if so, to examine which MAPKs are involved in MUC5AC gene suppression.
MATERIALS AND METHODS

Cell culture

NCI-H292 cells were purchased from the American Type Culture Collection (Rockville, MD) and cultured in Roswell Park Memorial Institute (RPMI) 1640 (Gibco BRL, Grand Island, NY) supplemented with 10% fetal bovine serum, 2 mM of L-glutamine, penicillin (100 μg/mL), and streptomycin (100 μg/mL) at 37°C in a humidified chamber with 95% air and 5% CO2. When cultures reached 70–80% confluency, cells were incubated in RPMI 1640 medium containing 0.5% fetal bovine serum for 24 hours.

Materials

Berberine was purchased from Sigma Co. (St. Louis, MO, USA). PD98059 (a specific inhibitor of ERK), and SB203580 (a specific inhibitor of p38 MAPK) were purchased from Calbiochem Biochemicals (San Diego, CA, USA). IL-1β was purchased from R&D Systems (Minneapolis, MN, USA) and anti-phospho-p44/42 MAPK (Thr202/Tyr204) antibody, anti-phospho-p38 MAPK (Thr180/Tyr182) antibody, and anti-phospho-SAPK/c-Jun NH2-terminal kinase MAPK (Thr183/Tyr185) antibody were purchased from Cell Signaling (Beverly, MA, USA).

Reverse Transcription (RT)-Polymerase Chain Reaction (PCR) of MUC5AC mRNA

Total cellular RNA was isolated from cultured NCI-H292 cells treated with IL-1β under each condition using Tri-Reagent (Molecular Research Center, Cincinnati, OH, USA). Total RNA (1 μg/20 μL) was reverse transcribed into cDNA using random hexanucleotide primers and Moloney murine leukemia virus reverse transcriptase (Gibco BRL), and MUC5AC cDNA was amplified by PCR using a PerkinElmer Cetus DNA Thermal Cycler (Perkin-Elmer, Norwalk, CT, USA) using previously described methods. A sequence of 5′ primer was CGACAACCTTCTGCGGTGC, and that of 3′ primer was GCCACTACCTCTTCCTGTCGTT. Amplification of each target gene was confirmed by sequencing (dsDNA Cycle Sequencing System; Gibco BRL) of PCR fragments.

Real-time PCR of MUC5AC mRNA

Primers and probes were designed with PerkinElmer Life Sciences Prime Express software and purchased from PE Biosystems (Foster City, CA, USA). Commercial reagents (Taqman PCR Universal PCR Master Mix, PerkinElmer Life Sciences) and conditions according to the manufacturer’s protocol were applied. An amount of 1 μg of cDNA (reverse transcription mixture) and oligonucleotides at a final concentration of 800 nM of primers and 200 nM of TaqMan hybridization probes were analyzed in a 25 μL volume. The real time-PCR probe was labeled with carboxyfluorosein (FAM) at the 5′ end and with a quencher carboxytetrarmethylrhodamine (TARMA) at the 3′ end. MUC5AC, β2M primers and TaqMan probe were designed as follows: MUC5AC (forward: 5′-CAGCTACCGTCCCTCAATTA-3′ and reverse: 5′-ACCCTCAGCGATGCCCTATGAG-3′), β2M (forward: 5′-CGCTCGTGCGCTTTTACGTA-3′ and reverse: 5′-GAGTACGCTGGATAGCCTCAA-3′), and Taqman probe 6FAM-CCTGCCATCCCTCCCGGTA (TARMA), β2M (forward: 5′-CGCTCGTGCGCTTTTACGTA-3′ and reverse: 5′-GAGTACGCTGGATAGCCTCAA-3′), and Taqman probe 6FAM-CCTGCCATCCCTCCCGGTA (TARMA). Real-time PCR was performed on a PerkinElmer Life Sciences ABI PRISM 7700 Sequence Detection System using previously described methods. Data are expressed as means ± SD. A minimum of at least three independent experiments were performed for each measurement. Differences between treatment groups were assessed by ANOVA with post hoc test, and the statistical significance was accepted for p values <0.05.

Western blot analysis

Cells were scraped into 1 mL of radioimmunoprecipitation assay buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS). Protein concentration was measured by bichinchonic acid protein assay using bovine serum albumin. Cell lysates were centrifuged and supernatants were subjected to Western blot. Each lane was added with 30 μg of protein, and electrophoresis was performed. Proteins were separated by 8% SDS-PAGE and transferred onto a nitrocellulose membrane. Blots were blocked with 10% non-fat dry milk in Tris-buffered saline with 0.05% Tween-20 (TBST) at 4°C for 12 h and probed with anti-p-ERK (1:1,000), anti-p-p38 MAPK (1:1,000), and anti-p-JNK (1:1,000) antibody for 4 h at room temperature. In addition, expression of MUC5AC protein was assessed with anti-MUC5AC antibody (1:1,000, Santa Cruz Biotechnology, Santa Cruz, CA, USA). After washing, blots were treated with horseradish peroxidase-conjugated secondary antibody (Amersham Pharmacia Biotech, Piscataway, NJ, USA) diluted to 1:5,000 in TBST for 1 h and
washed several times. Enhanced chemiluminescence and autoradiography were used for detection of bands. Blots were stripped and probed with α-tubulin antibody (Santa Cruz Biotechnology) to normalize for loading.

**Cell proliferation assay**

Cells were plated in 96-well plates at a density of 2,000 cells/well. After incubation for 16 hours, cells were washed with phosphate-buffered saline and incubated for 24 hours in serum-free medium containing varying concentrations of berberine. Cell proliferation was measured using a Cell Titer 96 Aqueous One Solution Proliferation Assay Kit (Promega Inc., Madison, WI) using as previously described. The mean percentage of living cells was calculated as follows: \([1-(\text{mean O.D. of experimental group/mean O.D. of control})] \times 100\). Experiments were performed more than 3 times, and statistical significance was accepted for p values <0.05 through the repeated measures ANOVA and multiple comparisons analysis.

**RESULTS**

**Berberine suppresses IL-1β-induced MUC5AC mRNA expression**

In a previous study, IL-1β maximally induced MUC5AC mRNA at a concentration of 10 ng/mL and incubation time of 24 h. Therefore, we used a 10 ng/mL concentration of IL-1β and 24 hour incubation time for experiments in this study. NCI-H292 cells were pretreated with berberine at concentrations of 0, 5, 25, and 50 μM 1 h before adding 10 ng/mL of IL-1β. After adding IL-1β to the cells, RT-PCR and real-time PCR for MUC5AC mRNA expression was performed. In comparison with the control which was not treated with either IL-1β or berberine, the relative ratio of MUC5AC mRNA expression at 0, 5, 25, and 50 μM of berberine was 5.2±0.6, 2.8±0.5, 1.1±0.3, 0.8±0.3. From 25 μM of berberine, IL-1β-induced MUC5AC mRNA expression was significantly suppressed which was in a dose-dependent manner (p<0.05)(Fig. 1A, B). To evaluate the cytotoxicity of berberine, cell viability was examined. Compared with the control, the percentage of living cells in 5, 25, and 50 μM of berberine was 93.6±4.1%, 86.0±5.8%, 68.4±7.3%. In 25 μM berberine, there was no significant suppression by berberine on cell viability was observed compared to the control group. Therefore, we found that berberine directly suppressed IL-1β-induced MUC5AC mRNA expression, not by its cytotoxicity.

![Fig. 1. Suppression of IL-1β-induced MUC5AC gene expression by berberine. RT-PCR (A) and real-time PCR (B) for MUC5AC mRNA expression show that expression of MUC5AC mRNA is significantly suppressed after treatment with 25 μM berberine in a dose-dependent manner. C: The percentage of living cells determined by cell proliferation assay. *: p<0.05.](image)

We used a berberine concentration of 25 μM for other experiments.

**Suppression of IL-1β-induced MUC5AC gene and protein expression by berberine**

NCI-H292 cells were pretreated with 25 μM berberine for 1 hour and then treated with 10 ng/mL of IL-1β. In comparison with the control that was not treated with either IL-1β or berberine, expression of MUC5AC mRNA in cells treated only with IL-1β increased by 4.8±0.7-fold, but in cells pretreated with berberine, the expression was significantly decreased by 1.2±0.2-fold (p<0.05)(Fig. 2A). In Western blot analysis, IL-1β induced expression of MUC5AC protein, but pretreatment with berberine decreased expression of IL-1β-induced MUC5AC protein to the control level (Fig. 2B).
ERK- and p38 MAPK-dependent suppression of IL-1β-induced MUC5AC mRNA expression by berberine

To determine which MAPKs were activated in NCI-H292 cells stimulated by IL-1β, we performed Western blot analysis using phospho-specific antibodies. ERK and p38 MAPKs were maximally activated 30 minutes after treatment with IL-1β, and this effect decreased after 60 minutes (Fig. 3A). Therefore, the incubation time to check changes in MAPK expression by berberine was determined as 30 min. NCI-H292 cells were pretreated with 25 μM of berberine for 1 hour, and then 10 ng/mL of IL-1β was added. After 30 min incubation, activation of p-ERK and p-p38 MAPK was significantly decreased to the control level in comparison with the IL-1β alone-treated group (Fig. 3B).

To confirm the possible involvement of the ERK and p38 MAPK pathways in IL-1β-induced MUC5AC gene expression, 20 μM of PD98059 and 20 μM of SB203580 were separately added to cells 1 hour before their treatment with IL-1β. Pretreatment with PD98059 suppressed expression of p-ERK; however, expressions of ERK and p-p38 remained unchanged. Conversely, pretreatment with SB203580 suppressed expression of p-p38, but p-ERK and ERK expressions did not change. These results showed that PD98059 and SB203580 clearly inhibited the ERK and p38 MAPK pathways, respectively (Fig. 4A). Under this experimental condition, we checked whether the ERK and p38 MAPK pathways were involved in the suppression of IL-1β-induced MUC5AC expression by berberine. When cells were treated with IL-1β only, the relative ratio of MUC5AC expression compared with the control was 5.0 ± 0.8. When specific inhibitors for ERK or p38 MAPK were added, the relative ratio of MUC5AC expression to the control was 1.3 ± 0.2 for cells pretreated with PD98059 and 0.9 ± 0.3 for cells pretreated with SB203580. Thus, MUC5AC expression induced by IL-1β was significantly suppressed by inhibiting the ERK or p38 MAPK signal transduction pathways (p<0.05)(Fig. 4B, C). These findings suggest that the ERK and p38 MAPK signaling pathways are involved in the suppression of MUC5AC expression by berberine.
DISCUSSION

Berberine is a quaternary ammonium salt from the group of isoquinoline alkaloids and is found in plants such as Berberis, goldenseal (Hydrastis canadenis), and Coptis chinensis in the roots, rhizomes, and stem bark. It has been known to have many pharmacological activities, including anti-microbial and anti-inflammatory activities. Kuo et al. found that berberine could inhibit cycloxygenase-2 expression and prostaglandin E production by regulating transcription factor activator protein 1. In addition, other studies showed that berberine induced IL-12 p40 production by activating p38 MAPK and α2-adrenergic receptor in mouse macrophages, and deviates CD4+ T cell from a Th2 to a Th1 response. Recently, some studies showed that berberine can inhibit lipopolysaccharide (LPS)-stimulated myocardial TNF-α secretion and improves LPS-induced contractile dysfunction in the intact heart. As mentioned, berberine shows many pharmacologic activities, but there is no evidence that berberine can suppress mucin secretion in human airway epithelium. Among 11 mucin genes expressed in the airways, MUC5AC has been reported to be associated with the pathogenesis of chronic inflammatory airway diseases. Many cytokine mediators, including TNF-α, and bacterial products induce mucin gene expression in the airways. Since MUC5AC is up-regulated by TNF-α via NF-κB activation, we thought that berberine could be somewhat involved in the down-regulation of MUC5AC expression, which we examined in this study.

In this study, when cells were pretreated with 25 μM of berberine, expressions of MUC5AC mRNA and protein were significantly suppressed. This MUC5AC suppression was also observed in studies on [6]-gingerol, quercetin, curcumin, and EGCG. Berberine has been reported to inhibit protein synthesis and cell cycle progression and to induce apoptosis in different cancer cells. In this study, berberine had no cytotoxic effect on NCI-H292 cells at 25 μM. These results indicate that berberine-induced suppression of MUC5AC expression was not the result of cytotoxic effects. Even though some polyphenols such as [6]-gingerol, quercetin, curcumin, and EGCG suppress MUC5AC expression induced by IL-1β, the minimal concentrations to suppress MUC5AC expression are different. It may be due to the characteristic of the materials, and potency and toxicity of these polyphenols and berberine need to be examined before they could be clinically used.

To clarify the mechanism through which berberine suppresses IL-1β-induced MUC5AC gene expression, Western blot analysis on MAPKs was done. MAPKs are important enzymes in the production of mucin, and they also play a significant role in cell proliferation, differentiation, apoptosis, cytoskeletal remodeling, and cell cycle. In the previous study on the activation of MAPK by IL-1β, the involvement of ERK and p38 MAPKs was revealed. In this study, ERK and p38 MAPKs which were activated by IL-1β treatment were suppressed by the pretreatment with 25 μM berberine. Therefore, we could infer that these MAPKs are involved in the regulation of MUC5AC suppression by berberine. To further investigate the involvement of ERK and p38 MAPKs, we performed the inhibitor study using specific inhibitors on ERK and p38 MAPKs. As a result, either the ERK- or p38 MAPK-specific inhibitors suppressed IL-1β-induced MUC5AC gene expression. Thus, the ERK and p38 MAPK signal transduction pathways are involved in suppression of MUC5AC gene expression by berberine. In the study on [6]-gingerol, quercetin, and EGCG, MUC5AC expression was also suppressed. Thus, this finding coincides with our result regarding berberine. However, there may be other pathways involved in the suppression of MUC5AC expression other than the
ERK and p38 MAPK signal transduction pathways because MAPK is an early activated signal transduction pathway. Thus, further studies are necessary to reveal the whole mechanisms.

CONCLUSION

Berberine, a natural alkaloid, significantly suppressed IL-1β-induced MUC5AC gene expression in human airway epithelial cells via the ERK- and p38 MAPK-dependent signal transduction pathways. Therefore, berberine may be considered as a possible anti-hypersecretory agent for inflammatory airway diseases.

Acknowledgments

This paper is a master's thesis of the first author.

REFERENCES